Ask Warren

JONBUR Research · Initiation

You're reading an earlier report from Oct 18, 2026. See the latest report

DongKook Pharmaceutical · 086450 · Biotech & Pharma

DongKook Pharmaceutical: Steady Growth and a Sharp Share Price Rise, With a Model Estimate Below the Market Price

Why this report

Start of coverage: one of the 300 largest companies, written once its financial statements were in.

DongKook Pharmaceutical's share price closed at ₩25,300 on 2026-10-16, up 33.6% over one year, while revenue has grown every year since 2021 and the trailing operating margin is 10.5%. The valuation model's base estimate of ₩19,982 per share sits below the current price, and foreign ownership has fallen from 14.9% to 10.6% over 60 days.

Written Oct 18, 2026 · Data as of Oct 16, 2026 · 0 views

This is not financial advice. The report does not recommend buying or selling anything.

XfWATGr/in@

Thesis

The data supports a picture of a steadily growing mid-sized drug and consumer-health company. Revenue rose from ₩594.2B in 2021 to ₩926.9B in 2025, and the operating margin has stayed in a range of 9.1% to 11.0%. Trailing figures to H1 2026 show revenue of ₩979.6B and net income of ₩76.3B, so growth has continued.

What the data does not support is a clear link between the recent price move and the company's earnings. The shares are up 21.3% in one month and 31.2% in three months, and the P/E has moved to 15.0 from 11.7 at the end of 2025. The model estimate is below the current price. Foreign holders have been net sellers over 20 days, while institutions and retail investors were net buyers. News headlines mention a planned rename to DK Centurion, overseas activity and a trademark dispute, but the data does not quantify their effect on earnings.

Business overview

DongKook Pharmaceutical is a Biotech & Pharma company listed on KOSDAQ since 2007-05-29 and founded in 1968. It has 45,230,420 listed shares and a market capitalisation of about ₩1.14T. Its CEO is 송준호.

The filed numbers show consistent top-line growth: revenue growth was 10.5% in 2023, 11.1% in 2024 and 14.1% in 2025. News items refer to a consumer brand, Centellian24, and to participation in an international pharma trade event. The data does not provide a breakdown of revenue by product or segment.

Every earlier JONBUR Research report and update note on DongKook Pharmaceutical, with Pro.

Unlock with Pro

Model estimate of fair value

Bear
₩9,739
-60%
Base
₩19,982
-18%
Bull
₩37,577
+54%

Model estimate based on the assumptions shown. Not a price target and not a buy or sell signal.

Base case of the 5-year discounted cash flow model on the stock's Valuation tab (statements TTM to H1 2026; discount rate 7.5%). Bear and Bull move the main assumptions by fixed steps. See and change the assumptions

Filings and data used

Report history

  1. Oct 21, 2026Update noteModel fair value changeDongKook Pharmaceutical: Model Fair Value Estimate Rises 69% to ₩33,780 Per Share
  2. Oct 18, 2026InitiationStart of coverage (300 largest)DongKook Pharmaceutical: Steady Growth and a Sharp Share Price Rise, With a Model Estimate Below the Market Price

Built only from jonbur's own data: prices and investor flows, filed financial statements and filings, and news headlines. Disclosed (filed) data is labelled as such. Written by AI and may contain mistakes.

This is not financial advice. The report does not recommend buying or selling anything.

Source: KRX statistical information